Thursday broker round-up UPDATE
BAE Systems: Investec downgrades from hold to sell with a target price of 430p.
BAE Systems
1,340.00p
16:45 23/04/24
Cobham
164.50p
14:03 17/01/20
Consort Medical
1,010.00p
16:35 05/03/20
Countrywide
394.80p
16:35 05/03/21
Dechra Pharmaceuticals
3,866.00p
08:01 16/01/24
Europa Metals Ltd NPV (DI)
1.40p
16:55 23/04/24
Ferrexpo
52.20p
16:40 23/04/24
FTSE 100
8,044.81
16:49 23/04/24
Go-Ahead Group
1,546.00p
16:34 07/10/22
Halma
2,236.00p
17:05 23/04/24
Lekoil Ltd (DI)
0.95p
14:19 17/05/22
Mattioli Woods
792.00p
17:15 23/04/24
Ophir Energy
57.50p
16:39 21/05/19
Polymetal International
215.00p
16:35 31/07/23
RPS Group
221.00p
16:39 23/01/23
Sky
1,727.50p
16:34 06/11/18
UBM
1,080.00p
16:44 15/06/18
Xaar
112.00p
16:40 23/04/24
British Sky Broadcasting: Credit Suisse ups target price from 600p to 630p and reiterates an underperform rating.
Cobham: Investec lowers target price from 290p to 280p and stays with its reduce rating.
Consort Medical: Numis reduces target price from 1120p to 910p downgrading from buy to hold.
Countrywide: Beaufort upgrades to buy.
Dechra Pharmaceuticals: Jefferies initiates with a target price of 871p and a buy recommendation.
Ferrum Crescent: Beaufort downgrades to hold.
Go-Ahead Group: Panmure Gordon raises target price from 2500p to 2900p maintaining its buy recommendation.
Halma: Liberum Capital initiates with a target price of 600p and a hold recommendation.
Lekoil: Morgan Stanley moves target price from 95p to 105p retaining an overweight rating.
Mattioli Woods: N+1 Singer raises target price from 394p to 470p upgrading from hold to buy.
Ophir Energy: Westhouse Securities shifts target price from 245p to 250p keeping an add rating.
Polymetal: Credit Suisse ups target price from 520p to 550p and upgrades to neutral.
RPS Group: JP Morgan cuts target price from 311p to 263p and keeps a neutral rating.
UBM: Berenberg reduces target price from 670p to 580p, while leaving its hold recommendation unchanged.
Xaar: FinnCap places both its target price (prev.: 450p) and its hold recommendation under review.